Sangamo Therapeutics Inc (SGMO) Actualités

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form EFFECT - Notice of Effectiveness

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry...

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third...